ZTS — Zoetis Inc.

Zoetis (ZTS) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $2.4 billion, up 1% reported and 4% on an organic operational basis.
• Adjusted Net Income: $754 million, a 5% increase reported and 9% on an organic operational basis.
• Companion Animal Revenue: $1.7 billion, growing 2% operationally.
• Livestock Revenue: $725 million, up 10% organically.
• Adjusted Gross Margin: 71.6%, an increase of 90 basis points.
• Adjusted Diluted EPS: Grew 7% operationally and 12% on an organic basis.

2. Strategic Updates and Business Highlights

• Companion Animal Segment:

  • Simparica franchise grew 7% operationally, with strong international performance.
  • Key Dermatology franchise grew 3%, driven by Apoquel Chewable adoption.
  • Osteoarthritis (OA) pain franchise declined 11% due to competitive pressures and social media misperceptions.

• Livestock Segment:

  • Achieved 10% organic operational growth, supported by strong demand and execution in poultry and vaccines.

• Innovation Pipeline:

  • New long-acting OA drugs (Lenivia and Portela) expected to launch in 2026, with a focus on education and awareness to ensure successful adoption.
  • Continued investment in manufacturing capabilities to support product launches.

3. Forward Guidance and Outlook

• Revised Full-Year Revenue Guidance: $9.4 billion to $9.475 billion, with organic operational growth projected at 5.5% to 6.5%.
• Adjusted Net Income Guidance: Expected to be between $2.8 billion and $2.84 billion, with organic operational growth of 5.5% to 7%.
• Confidence in Long-Term Growth: Despite near-term challenges, Zoetis remains optimistic about its portfolio and market opportunities.

4. Challenges and Points of Concern

• Moderating Growth: Growth in the U.S. Companion Animal segment has slowed, with therapeutic visits declining, impacting new patient starts.
• Competitive Pressures: Increased competition in dermatology and OA pain segments, particularly from new product launches, is affecting market share.
• Osteoarthritis Franchise Decline: Librela sales faced a 15% operational decline, attributed to negative perceptions and competitive dynamics.
• Therapeutic Visit Declines: Sustained declines in therapeutic visits over the last three quarters have raised concerns about future growth.

5. Notable Q&A Insights

• Market Dynamics: Executives acknowledged the impact of declining therapeutic visits on growth, emphasizing the need for improvement in this area to drive new patient starts.
• Competitive Landscape: The introduction of new competitors has created pressure, but Zoetis maintains confidence in its product differentiation and market position.
• Stabilization of Librela: Signs of stabilization in Librela sales were noted, with expectations for recovery in 2026.
• Future Guidance: While there are challenges, management expressed optimism about returning to growth in key franchises and maintaining long-term growth trajectories.

Overall, Zoetis reported solid financial results for Q3 2025, but faces challenges in certain segments due to competitive pressures and declining therapeutic visits. The company remains focused on innovation and strategic initiatives to drive future growth.